Table 2 Monitored treatment-related complications and comorbidities during one year of follow-up
Phone call 1 | Phone call 2 | Phone call 3 | Phone call 4 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Prevalence of complications | Month 3 (n = 115) | Month 6 (n = 113) | Month 9 (n = 106) | Month 12 (n = 104) | Total | (n = 115) | ||||
n | % | n | % | n | % | n | % | n | % | |
Treatment-related complications | ||||||||||
Neuropathy | ||||||||||
Peripheral | 26 | 22.6 % | 24 | 21.2 % | 22 | 20.7 % | 17 | 16.3 % | 28 | 24.3 % |
Central | 1 | 0.9 % | 2 | 1.8 % | 0 | 0.0 % | 2 | 1.9 % | 2 | 1.7 % |
Infections | ||||||||||
Pulmonary | 14 | 12.2 % | 8 | 7.1 % | 8 | 7.5 % | 8 | 7.7 % | 38 | 33.0 % |
Ear, nose and throat | 5 | 4.4 % | 5 | 4.4 % | 8 | 7.5 % | 5 | 4.8 % | 23 | 20.0 % |
Urinary | 4 | 3.5 % | 4 | 3.5 % | 3 | 2.8 % | 2 | 1.9 % | 13 | 11.3 % |
Hypogammaglobulinaemia | 15 | 13.0 % | 36 | 31.9 % | 43 | 40.6 % | 31 | 29.8 % | 54 | 47.0 % |
Gastritis/ulcer | 14 | 12.2 % | 17 | 15.0 % | 18 | 17.0 % | 11 | 10.6 % | 20 | 17.4 % |
Arthralgia | 52 | 45.2 % | 57 | 50.4 % | 47 | 44.3 % | 44 | 42.3 % | 74 | 64.3 % |
Libido decrease | 16 | 13.9 % | 7 | 6.2 % | 10 | 9.4 % | 10 | 9.6 % | 17 | 14.8 % |
Erectile dysfunction (n = 64) | 11 | 17.2 % | 6 | 9.5 % | 7 | 10.9 % | 6 | 10.2 % | 20 | 31.3 % |
Osteoporosis | 9 | 7.8 % | 10 | 8.9 % | 9 | 8.5 % | 12 | 11.5 % | 15 | 13.3 % |
Comorbidities | ||||||||||
Cardiovascular complications (≥1/phone call) | 6 | 5.2 % | 4 | 3.5 % | 6 | 5.7 % | 10 | 9.6 % | 16 | 13.9 % |
Disorders of thyroid gland | 5 | 4.4 % | 5 | 4.4 % | 4 | 3.8 % | 7 | 6.7 % | 7 | 6.1 % |
Disorders of prostate (n = 64) | 3 | 4.7 % | 2 | 3.2 % | 2 | 3.1 % | 2 | 3.1 % | 3 | 4.7 % |
Second cancer | 1 | 0.9 % | 1 | 0.9 % | 1 | 0.9 % | 2 | 1.9 % | 4 | 3.5 % |